

Alexa Hetzel, PA-C

APPOINTMENTS/EMPLOYMENT

Academic Appointments:

9/2015-5/2018 Physician Assistant Student, Monmouth University
9/2017-5/2018 Graduate Assistant, Monmouth University
8/2008-5/2012 Penn State University, Bachelor of Science in Kinesiology
8/2011-12/2011 Teaching Assistant
Fitness with Exercise Physiology

Employment:

3/2015-7/2015 Clinical Research Coordinator
Psoriasis Treatment Center of Central New Jersey
9/2016-7/2015 Certified Medical Assistant
Windsor Dermatology, PC

GAPS IN EMPLOYMENT *None*

EDUCATION

9/2015-5/2018 M.S. in Physician Assistant
Monmouth University, New Jersey
8/2008-5/2012 B.S. in Kinesiology
The Pennsylvania State University, University Park, PA
9/2004-6/2008 Graduated
Metuchen High School, Metuchen New Jersey

CERTIFICATION

9/2017 Advanced Life Support
9/2017 Basic Life Support
5/2018 NCCPA

LICENSURE

7/2018 Physicians Assistant license #**25MP00479400**
7/2018 CDS # **A00327500**
7/2018 DEA #**MH4870350**

HONORS/AWARDS

2018 Phi Alpha National Honor Society
2009- 2012 Academic All Big Ten

MEMBERSHIPS IN PROFESSIONAL ORGANIZATIONS

9/2017- Present New Jersey Society of Physician Assistants
5/206-Present American Academy of Physician Assistants

OTHER PROFESSIONAL ROLES

9/2015-10/2016 Monmouth University Student Society President

GRANTS, CONTRACTS, FOUNDATION SUPPORT *None*

RESEARCH PROFILE

Research

2/2017-5/2018 Utilization of Physician Assistants by Physicians and Pharmacists for their personal use

CLINICAL TRIAL PARTICIPATION

<i>Dates</i>	<i>Project</i>	<i>Role in Project</i>	<i>Sponsored by</i>	<i>Other Info</i>
2020	Open Label Study, Evaluating Taltz in combination with Enstilar (calcipotriene and betamethasone dipropionate) Foam in Psoriasis Patients.	Sub-Investigator	Jerry Bagel.	
2020	A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants with Moderate to Severe Hidradenitis Suppurativa.	Sub-Investigator	UCB	
2020	A Single Center Study to Evaluate the Effectiveness and Safety of ILUMYA in Combination with HALOG Ointment 0.1% for the Treatment of Moderate to Severe Plaque Psoriasis.	Sub-Investigator	Jerry Bagel	
2020	A Phase 3, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151	Sub-Investigator	Arcutis, Inc.	

	Cream 0.3% Administered QD in Subjects with Chronic Plaque Psoriasis.			
2020	A pragmatic trial of home versus office based narrow band ultraviolet B phototherapy for the treatment of psoriasis.	Sub-Investigator	PCORI	
2019	Open Label Study Evaluating DUOBRII in Psoriasis Patients Being Treated with Biologic Agents.	Sub-Investigator	Jerry Bagel	
2019	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Plaque Psoriasis of the Scalp.	Sub-Investigator	Sun Pharma	
2019	Multi-center, double-blind, randomised, placebo-controlled, phase IIb dose-finding study to evaluate efficacy and safety of different subcutaneous doses of BI 655130 in patients with moderate to severe Palmoplantar Pustulosis (PPP).	Sub-Investigator	Boehringer Ingelheim	
2019	A Phase 3 Efficacy and Safety Study of Tapinarof for the Treatment of Plaque Psoriasis in Adults.	Sub-Investigator	Dermavant Sciences	
2019	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Risankizumab Using a New Formulation for the Treatment of Adult Subjects with Moderate to Severe Plaque Psoriasis.	Sub-Investigator	Abbvie	
2019	A 16 week, Randomized, Open Label, Multicenter Study to Assess the Superiority of Secukinumab over Guselkumab in the Complete Treatment of Ustekinumab-Resistant Psoriatic Plaques- Arrow.	Sub-Investigator	Novartis	
2019	A Phase 2B, Randomized, Double Blind, Vehicle Controlled, Parallel-Group, Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream Applied Once or Twice Daily for 12 Weeks in Participants with Mild to Moderate Chronic Plaque Psoriasis.	Sub-Investigator	Pfizer	
2019	An Outcomes Study to Determine the Reasons Patients on Biologic Therapy Discontinue Treatment and Fail to Follow-up With Their Providers.	Sub-Investigator	Jerry Bagel	
2019	A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Immune-Mediated Inflammatory Skin	Sub-Investigator	Target Pharasolutions	

	Conditions.			
2019	A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Risankizumab in Adult and Adolescent Subjects with Moderate to Severe Atopic Dermatitis.	Sub-Investigator	Abbvie	
2019	Risankizumab versus Secukinumab for Subjects with Moderate to Severe Plaque Psoriasis.	Sub-Investigator	Abbvie	
2018	A Phase 3, Multicenter, Randomized, Double-Blind Study with an Active-Controlled Initial Treatment Period Followed by a Dose-Blind Maintenance Treatment Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects with Moderate to Severe Chronic Plaque Psoriasis.	Sub-Investigator	UCB	
2018	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo and Active Comparator-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects with Moderate to Severe Chronic Plaque Psoriasis.	Sub-Investigator	UCB	
2018	A Randomized, Double Blind, Placebo Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritis in Adults with Prurigo Nodularis.	Sub-Investigator	Menlo Therapeutics	
2018	A Study to Evaluate the Safety and Efficacy of Brodalumab in Subjects with Moderate to Severe Plaque Psoriasis Who Have Failed IL-17A Therapies. .	Sub-Investigator	Ichan School of Medicine at Mount Siani	
2018	A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritis in Adults with Plaque Psoriasis.	Sub-Investigator	Menlo Therapeutics	
2018	A Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Tralokinumab on Vaccine Antibody Responses in Adults with Moderate-to-Severe Atopic Dermatitis Who are Candidates for Systemic Therapy.	Sub-Investigator	Leo Pharma	
2018	A Multi-Center, Long-Term Extension to Evaluate the Long-Term Safety and Maintenance of Treatment Effect of Mirikizumab in Patients with Moderate-to-Severe Plaque Psoriasis.	Sub-Investigator	Eli Lilly	

2018	An Open-Label, Observational Study Evaluating Enstilar® (calcipotriene and betamethasone dipropionate) Foam, 0.005%/0.064% QD in Psoriasis Patients Being Treated with Etanercept or Adalimumab.	Sub-Investigator	Jerry Bagel	
2018	A Single Center Study to Evaluate the Effectiveness and Safety of add on Enstilar® in Patients Using Otezla for Moderate to Severe Plaque Psoriasis.	Sub-Investigator	Jerry Bagel	
2018	A 24-Week Multicenter, Randomized, Double-Blind Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis.	Sub-Investigator	Eli Lilly	
2018	A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis.	Sub-Investigator	Abbive	
2018	A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study with Randomized Withdrawal and Retreatment to Evaluate the Efficacy and Safety of BMS-986165 in Subjects with Moderate-to-Severe Plaque Psoriasis.	Sub-Investigator	Bristol-Myers Squibb	
2018	A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects with Mild to Moderate Plaque Psoriasis	Sub-Investigator	Celgene Corporation	
2018	A Phase 3, Multicenter, Randomized, Placebo and Active Comparator Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Subjects (≥6 To <18 Years of Age).	Sub-Investigator	Janssen	
2018	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients with Moderate-to-Severe Plaque Psoriasis.	Sub-Investigator	Eli Lilly	
2018	Phase II Evaluation of Safety, Tolerability, and Efficacy of BI 730357 in Patients with Moderate-to-Severe Plaque Psoriasis.	Sub-Investigator	Boehringer Ingelheim	

2018	Dupixent Atopic Dermatitis Photography Project.	Sub-Investigator	Sanofi	
2018	Skin Biopsy Analysis for Inflammatory Skin Disorders.	Sub-Investigator	Jerry Bagel	
2018	A Randomized, Double-Blind, Multicenter Study Assessing Short (16 Weeks) and Long-Term Efficacy (Up to 1 Year), Safety, and Tolerability of Sub-Cutaneous Secukinumab in Subjects of Body Weight 90kg or Higher with Moderate to Severe Chronic Plaque-Type Psoriasis.	Sub-Investigator	Novartis	
2018	A Randomized, Double-Blind, Placebo Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritis in Adults with Prurigo Nodularis.	Sub-Investigator	Menlo Therapeutics Inc.	
2018	An Open-Label Long-Term Safety Study of Serlopitant for the Treatment of Pruritis. Sponsored by Menlo Therapeutics Inc.	Sub-Investigator	Menlo Therapeutics Inc.	
2018	A Prospective Observational Study of Adult Patients Receiving Dupixent for Atopic Dermatitis.	Sub-Investigator	Regeneron	
2018	A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects with Moderate to Severe Plaque Psoriasis who are Candidates for Systemic Therapy.	Sub-Investigator	Abbvie	
2018	A Phase 3, Multicenter, Randomized, Double Blind Placebo and Active Comparator Controlled Parallel Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects with Moderate to Severe Plaque Psoriasis.	Sub-Investigator	UCB Biopharma SPRL	
2018	A Phase 3, Multicenter, Randomized, Double Blind Study With an Active Controlled Initial Treatment Period Followed by a Dose Blind Maintenance Treatment Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects with Moderate to Severe Plaque Psoriasis.	Sub-Investigator	UCB Biopharma SPRL	
2018	Randomized, Double Blind, Placebo Controlled Study of the Efficacy, Safety and Tolerability of Selopitant for the Treatment of Pruritus in Adults with Plaque Psoriasis.	Sub-Investigator	Menlo Therapeutics Inc.	

2015	A Phase III, Multi-Center, Double-Blind, Randomized, Vehicle Controlled Clinical Study To Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis	Principal Investigator	Dow Pharmaceutical Sciences	
2015	A Phase III, Multi-Center, Open Label Study to Evaluate the Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis	Principal Investigator	Dow Pharmaceutical Sciences	
2015	A Multi-Center, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Ixekizumab Dosing Regimens in Patients with Moderate-to-Severe Plaque Psoriasis	Principal Investigator	Eli Lilly and Company	
2015	An Open Label Extension Trial Assessing the Safety and Efficacy of BI 655066 Administered Subcutaneously in Patients with Moderate to Severe Chronic Plaque Psoriasis	Principal Investigator	Boehringer Ingelheim Pharmaceuticals, Inc	
2015	A Prospective, Observational, US-Based Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed with Mycosis Fungoides Cutaneous T-Cell Lymphoma and Treated with Valchlor	Principal Investigator	Actelion Pharmaceuticals US, Inc	

2015	A Phase IV, Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Study of the Efficacy and Safety of Apremilast (CC-10004), in Subjects with Moderate Plaque Psoriasis	Principal Investigator	Celgene Corporation	
2015	An Open-Label Study of Dupilimab in Patients with Atopic Dermatitis who participated in Previous Dupilimab Clinical Trials	Principal Investigator	Regeneron Pharmaceuticals, Inc	
2015	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of Multiple Dupilimab Dose Regimens Administered as Monotherapy For Maintaining Treatment Response in Patients with Atopic Dermatitis	Principal Investigator	Regeneron Pharmaceuticals, Inc	<i>Lancet.</i> 2017 May 4. pii: S0140-6736(17)31191-1. doi: 10.1016/S0140-6736(17)31191-1. [Epub ahead of print] Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Blauvelt A ¹ , de Bruin-Weller M ² , Gooderham M ³ , Cather JC ⁴ , Weisman J ⁵ , Pariser D ⁶ , Simpson EL ⁷ , Papp KA ⁸ , Hong HC ⁹ , Rubel D ¹⁰ , Foley P ¹¹ , Prens E ¹² , Griffiths CEM ¹³ , Etoh T ¹⁴ , Pinto PH ¹⁵ , Pujol RM ¹⁶ , Szepietowski JC ¹⁷ , Ettler K ¹⁸ , Kemény L ¹⁹ , Zhu X ²⁰ , Akinlade B ²¹ , Hultsch T ²² , Mastey V ²¹ , Gadkari A ²¹ , Eckert L ²³ , Amin N ²¹ , Graham NMH ²¹ , Pirozzi G ²⁴ , Stahl N ²¹ , Yancopoulos GD ²¹ , Shumel B ²¹ .
2015	Single-Center, Two Phase, Pilot Study to Evaluate the Efficacy and Safety of Combining Otezla® (apremilast) 30mg	Principal Investigator	Jerry Bagel, MD	

	BID in Combination with Narrowband UVB (nUVB) Phototherapy, to Determine Effectiveness of Otezla® in Promoting Maintenance of Response in the Treatment of Moderate-to-Severe Plaque Psoriasis			
2015	Randomized, Phase 2, Double-Blind, Vehicle-Controlled Trial to Evaluate the Safety and Efficacy of Q301 Cream in Patients with Moderate to Severe Atopic Dermatitis	Principal Investigator	Qurient	
2014	A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients with Moderate-To-Severe Atopic Dermatitis	Principal Investigator	Regeneron Pharmaceuticals, Inc	<i>N Engl J Med.</i> 2016 Dec 15;375(24):2335-2348. Epub 2016 Sep 30. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. Simpson EL ¹ , Bieber T ¹ , Guttman-Yassky E ¹ , Beck LA ¹ , Blauvelt A ¹ , Cork MJ ¹ , Silverberg JI ¹ , Deleuran M ¹ , Kataoka Y ¹ , Lacour JP ¹ , Kingo K ¹ , Worm M ¹ , Poulin Y ¹ , Wollenberg A ¹ , Soo Y ¹ , Graham NM ¹ , Pirozzi G ¹ , Akinlade B ¹ , Staudinger H ¹ , Mastey V ¹ , Eckert L ¹ , Gadkari A ¹ , Stahl N ¹ , Yancopoulos GD ¹ , Ardeleanu M ¹ ; SOLO 1 and SOLO 2 Investigators.
2014	A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Study Followed by A Dose-Blind and Open-Label Follow-Up to Evaluate the Efficacy and Safety of Certolizumab Pegol in	Principal Investigator	UBC Biopharma, SPRL	<i>Expert Opin Biol Ther.</i> 2017 Mar;17(3):387-394. doi: 10.1080/14712598.2017.1283401 . Epub 2017 Feb 6. Certolizumab pegol for the treatment of psoriasis. Campanati A ¹ , Benfaremo D ² , Luchetti MM ² , Ganzetti G ¹ , Gabrielli A ² , Offidani A ¹ .

	Subjects with Moderate to Severe Chronic Plaque Psoriasis			
2014	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo and Active Comparator-Controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects with Moderate to Severe Plaque-Type Psoriasis	Principal Investigator	Janssen Research & Development, LLC	<i>J Am Acad Dermatol.</i> 2017 Mar;76(3):405-417. doi: 10.1016/j.jaad.2016.11.041. Epub 2017 Jan 2. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. Blauvelt A ¹ , Papp KA ² , Griffiths CE ³ , Randazzo B ⁴ , Wasfi Y ⁵ , Shen YK ⁵ , Li S ⁵ , Kimball AB ⁶ .
2014	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Demonstrate the Efficacy of Subcutaneous Secukinumab [300mg] as Assessed by the Psoriasis Scalp Severity Index (PSSI) at 12 Weeks of Treatment, Compared to Placebo, and Assess Safety and Tolerability Up to 24 Weeks in Adult Subjects with Moderate to Severe Scalp Psoriasis	Principal Investigator	Novartis Pharmaceuticals Corporation	<i>J Am Acad Dermatol.</i> 2017 Ahead of pub Jerry Bagel, MD, Kristina Callis Duffin, MD, MS, Angela Moore, MD, Laura K. Ferris, MD, PhD, Kimberly Siu, MD, MPH, Jennifer Steadman, MSW, Farid Kianifard, PhD, Judit Nyirady, MD, MBA, Mark Lebwohl, MD. The Effect of Secukinumab on Moderate-to-Severe Scalp Psoriasis: Results of a 24-Week, Randomized, Double-blind, Placebo-controlled Phase 3b Study.
2014	Characterization of Chronic Inflammatory Skin Disease	Principal Investigator	TRBIO	
2014	A Small Methods Study Involving Electronic Data Collection in Normal	Principal Investigator	HRA	

	Care Settings with Adult Psoriasis Patients Who Have A High Level of Clearance (As Determined by sPGA of 0 or 1) And Are Currently Being Treated With A Biologic			
2014	LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects with Psoriasis Vulgaris	Principal Investigator	Leo Pharma	<i>Skinmed.</i> 2017 Apr 1;15(2):119-124. eCollection 2017. Fixed-Combination Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam Is Well Tolerated in Patients with Psoriasis Vulgaris: Pooled Data from Three Randomized Controlled Studies. Menter A ¹ , Gold LS ² , Koo J ³ , Villumsen J ⁴ , Rosén M ⁴ , Lebwohl M ⁵ .
2014	A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle-Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis	Principal Investigator	Valeant	
2014	A Phase 3, Multicenter, Double-Blind, Randomized, Parallel-Arm, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Adalimumab for Treatment of Nail Psoriasis in Subjects with Chronic Plaque Psoriasis	Principal Investigator	AbbVie	
2014	A 52-week, multicenter, randomized, double-blind study of subcutaneous secukinumab to demonstrate efficacy	Principal Investigator	Novartis	

	as assessed by Psoriasis Area and Severity Index at 16 weeks of treatment compared to ustekinumab and to assess long-term safety, tolerability and efficacy in subjects with Moderate to severe plaque psoriasis			
2014	A 48 weeks study of three different dose regimens of BI 655066 Administered subcutaneously in patients with moderate to severe Chronic plaque psoriasis (randomized, dose-ranging, active-comparator controlled (ustekinumab), double-blind within dose groups of BI 655066	Principal Investigator	Boehringer Ingelheim	<i>N Engl J Med.</i> 2017 Apr 20;376(16):1551-1560. doi: 10.1056/NEJMoa1607017. Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis. Papp KA ¹ , Blauvelt A ¹ , Bukhalo M ¹ , Gooderham M ¹ , Krueger JG ¹ , Lacour JP ¹ , Menter A ¹ , Philipp S ¹ , Sofen H ¹ , Tyring S ¹ , Berner BR ¹ , Visvanathan S ¹ , Pamulapati C ¹ , Bennett N ¹ , Flack M ¹ , Scholl P ¹ , Padula SJ ¹ .

PUBLICATIONS

- 2018 Baron H, Hetzel A, Fixler D, Trujillo B, Tulino J. Utilization of Physician Assistants by Physicians and Pharmacists. May 2018:1-21.
- 2017 Bagel J, Hetzel A. Biologics and Pediatric Psoriasis. *Practical Dermatology.* 2017;14(3):12-13.